$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Lorlatinib/lorlatinib clinical treatment of ros1
2026-02-01 22:25:32
Check Details
Lorlatinib/lorlatinib latest price
2026-02-01 22:25:32
Check Details
What are the side effects of lorlatinib/lorlatinib?
2026-02-01 22:25:32
Check Details
Laotian version of lorlatinib/lorlatinib: an affordable new option for lung cancer treatment
2026-02-01 22:25:32
Check Details
Discussion on the monthly treatment cost of lorlatinib/lorlatinib
2026-02-01 22:25:32
Check Details
Clinical study of lorlatinib/lorlatinib in the treatment of ROS1-positive non-small cell lung cancer
2026-02-01 22:25:32
Check Details
Lorlatinib/Lorlatinib: New Trends in Market Prices
2026-02-01 22:25:32
Check Details
What are the adverse reactions of lorlatinib/lorlatinib?
2026-02-01 22:25:32
Check Details
Is there a fourth generation of resistance to lorlatinib/lorlatinib?
2026-02-01 22:25:32
Check Details
Can lorlatinib/lorlatinib cure lung cancer?
2026-02-01 22:25:32
Check Details
Lorlatinib/lorlatinib API 3922
2026-02-01 22:25:32
Check Details
How many days does it take to see the effect of lorlatinib/lorlatinib?
2026-02-01 22:25:32
Check Details
1
2
...
699
700
701
702
703
704
705
...
10223
10224
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tivozanib: A Next-Generation Highly Selective VEGFR-Targeted Therapy Explained
2
Capmatinib Clinical Guide: Drug Comparisons, Treatment Strategies, and Combination Therapy Prospects
3
Avatrombopag Complete Guide: Efficacy, Indications, and TPO-RA Drug Comparisons
4
Pralsetinib Clinical Guide: Discontinuation Principles, Drug Comparisons, and Treatment Strategies
5
Venetoclax Clinical Guide: Mechanism, Indications, and Originator vs. Generic Comparison
6
Dabrafenib Clinical Guide: Indications, Combination Strategies, and BRAF Inhibitor Comparisons
7
Elagolix Side Effects and Safety Guide
8
Hetrombopag vs. Avatrombopag: Key Differences Between Two Oral TPO-RAs and Safety Considerations
9
Lytenava: The First FDA-Approved Ophthalmic Bevacizumab Formulation
10
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
11
Simtriyo (Centanafadine): World's First NDSRI ADHD Drug Approved by FDA
12
Lipfendra (Enlicitide): The World's First Oral PCSK9 Inhibitor Approved by FDA